Reported 3 days ago
Jefferies has reaffirmed its Buy rating for CVS Health Corporation (NYSE:CVS), setting a price target of $80. The updated rating follows the company’s fiscal Q2 2025 results, where CVS reported an 8.4% increase in revenues to $98.9 billion. Additionally, UBS also upgraded its rating on CVS to Buy with a $79.00 target, highlighting the stock's current undervaluation. CVS operates across various segments, including healthcare benefits and pharmacy services, positioning it as a major player in the health solutions market.
Source: YAHOO